Marinus Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer

Oppenheimer upgraded Marinus Pharmaceuticals to Outperform from Perform with a $6 price target. The firm views the risk/reward for the shares as attractive ahead of the Phase 3 TrustTSC topline results expected in early Q4. Key opinion leaders are expressing confidence in the trial design and likelihood for clinically meaningful efficacy, and a slower titration schedule compared to Phase 2 should improve both tolerability and efficacy, the analyst tells investors in a research note. Opco’s scenario analysis forecasts 75% probability adjusted upside for the shares.